These findings lead us to speculate that a biomarker panel consisting of L-FABP, BNP or NT-proBNP, and urinary or plasma NGAL may improve the early prediction of AKI in patients admitted to medical CICUs. The gene discussed is LCN2; the disease is acute kidney injury.